Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Can population BRCA screening be applied in non-Ashkenazi Jewish populations? Experience in Macau population.

Journal of medical genetics - 1 Sept 2021

Qin Zixin, Kuok Cheong Nang, Dong Hui, Jiang Luhan, Zhang Li, Guo Maoni, Leong Hio Kuan, Wang Lei, Meng Grace, Wang San Ming

Abstract excerpt

BACKGROUND: Pathogenic mutation in BRCA genes causes high cancer risk. Identifying the mutation carriers plays key roles in preventing BRCA mutation-related cancer. Population screening has demonstrated its power for comprehensive identification of the mutation carriers. However, it is only recommended for the Ashkenazi Jewish population with high prevalence of three founder mutations, but not for non-Ashkenazi...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cost-Benefit Analysis
Share to Genes, BRCA1

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genes, BRCA2

Share to Germ-Line Mutation

Share to Mass Screening

Share to Population Surveillance

Share to Prevalence

Source

Identifiers

PMID: 32817299
DOI: 10.1136/jmedgenet-2020-107181

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Can population BRCA screening be applied in non-Ashkenazi Jewish populations? Experience in Macau population.PMID 32817299Read ↗

A comparison of the detection of BRCA mutation carriers through the provision of Jewish population-based genetic testing compared with clinic-based genetic testingSemantic proximity Read ↗

Population-based BRCA1/BRCA2 screening in Ashkenazi Jews: a call for evidence.Semantic proximity Read ↗

Screening for founder mutations in BRCA1 and BRCA2 in unselected Jewish women.Semantic proximity Read ↗

Cost-effectiveness of population-based BRCA1/2 testing and ovarian cancer prevention for Ashkenazi Jews: a call for dialogue.Semantic proximity Read ↗

Identifying Ashkenazi Jewish BRCA1/2 founder variants in individuals who do not self-report Jewish ancestry.Semantic proximity Read ↗

Identifying Ashkenazi Jewish <i>BRCA1/2</i> founder variants in individuals who do not self-report Jewish ancestrySemantic proximity Read ↗

Population Based Testing for Primary Prevention: A Systematic ReviewSemantic proximity Read ↗

Population-Based BRCA1/2 Testing in Ashkenazi Jews: Ready for Prime Time.Semantic proximity Read ↗

Population-based Genetic Testing for Precision Prevention.Semantic proximity Read ↗

Cost-effectiveness of population screening for BRCA mutations in Ashkenazi jewish women compared with family history-based testing.Semantic proximity Read ↗

Cost effectiveness of population based BRCA1 founder mutation testing in Sephardi Jewish women.Semantic proximity Read ↗

Which BRCA genetic testing programs are ready for implementation in health care? A systematic review of economic evaluations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.